New hope for IBD patients: guselkumab under Real-World spotlight
NCT ID NCT07242248
First seen Nov 21, 2025 · Last updated May 21, 2026 · Updated 16 times
Summary
This study is tracking 220 adults in the UK with moderate to severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic treatment. Researchers want to see how well the drug controls symptoms and helps patients achieve remission without needing steroids. The goal is to understand how guselkumab performs in everyday medical practice, not just in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
London North West University Healthcare NHS Trust
RECRUITINGHarrow, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.